Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

医学 脂肪性肝炎 肝活检 肝硬化 脂肪肝 内科学 安慰剂 脂肪变性 临床试验 纤维化 胃肠病学 活检 病理 疾病 替代医学
作者
Stephen A. Harrison,Vlad Ratziu,Quentin M. Anstee,Mazen Noureddin,Arun J. Sanyal,Jörn M. Schattenberg,Pierre Bédossa,Mustafa R. Bashir,David J. Schneider,Rebecca Taub,Meena B. Bansal,Kris V. Kowdley,Zobair M. Younossi,Rohit Loomba
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:59 (1): 51-63 被引量:30
标识
DOI:10.1111/apt.17734
摘要

Summary Background Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. Aims To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]). Methods MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes. Conclusion The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei应助zhangjianzeng采纳,获得10
1秒前
tianliyan完成签到 ,获得积分10
1秒前
QYW发布了新的文献求助10
1秒前
cc完成签到,获得积分10
1秒前
嘟嘟发布了新的文献求助10
2秒前
花开发布了新的文献求助10
2秒前
英勇的冰旋完成签到,获得积分20
3秒前
3秒前
3秒前
专注慕晴发布了新的文献求助10
3秒前
5秒前
manman发布了新的文献求助20
6秒前
情怀应助不许内耗采纳,获得10
6秒前
6秒前
7秒前
安详的断缘完成签到,获得积分10
7秒前
7秒前
dj发布了新的文献求助10
12秒前
852应助整齐南莲采纳,获得10
12秒前
姚叔发布了新的文献求助10
12秒前
Jenny完成签到,获得积分10
13秒前
搜集达人应助ZHANG采纳,获得10
13秒前
ding应助WW采纳,获得10
16秒前
16秒前
惜墨驳回了aaa应助
16秒前
花开完成签到,获得积分20
18秒前
早日毕业完成签到,获得积分10
20秒前
Yziii应助manman采纳,获得20
20秒前
忧郁绣连应助wangxr采纳,获得20
20秒前
20秒前
20秒前
huchen发布了新的文献求助30
20秒前
充电宝应助嘟嘟采纳,获得10
21秒前
王哪儿跑完成签到,获得积分10
21秒前
奔奔完成签到,获得积分10
21秒前
21秒前
喵喵酱发布了新的文献求助10
23秒前
livra1058完成签到,获得积分10
23秒前
花盛完成签到,获得积分10
23秒前
默默毛豆发布了新的文献求助10
23秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137308
求助须知:如何正确求助?哪些是违规求助? 2788393
关于积分的说明 7786079
捐赠科研通 2444547
什么是DOI,文献DOI怎么找? 1299936
科研通“疑难数据库(出版商)”最低求助积分说明 625650
版权声明 601023